In the BioHarmony Drug Report Database

"Preview" Icon

Fingolimod

Gilenya (fingolimod) is a small molecule pharmaceutical. Fingolimod was first approved as Gilenya on 2010-09-21. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis and relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target transient receptor potential cation channel subfamily M member 7, G protein-activated inward rectifier potassium channel 4, sphingosine 1-phosphate receptor 3, sphingosine 1-phosphate receptor 2, and sphingosine 1-phosphate receptor 4. Gilenya’s patents are valid until 2032-03-30 (FDA).

 

Trade Name

 

Gilenya
 

Common Name

 

fingolimod
 

ChEMBL ID

 

CHEMBL314854
 

Indication

 

multiple sclerosis, relapsing-remitting multiple sclerosis
 

Drug Class

 

Immunomodulators

Image (chem structure or protein)

Fingolimod structure rendering